Stock Scorecard



Stock Summary for Pacira BioSciences Inc (PCRX) - $24.91 as of 3/28/2025 8:42:30 PM EST

Total Score

9 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PCRX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PCRX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PCRX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PCRX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PCRX (40 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PCRX

Pacira Surges 66.8% in Six Months: How Should You Play the Stock? 3/21/2025 4:39:00 PM
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual - Pacira BioSciences ( NASDAQ:PCRX ) 3/14/2025 8:05:00 PM
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual 3/14/2025 8:05:00 PM
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences - Pacira BioSciences ( NASDAQ:PCRX ) 3/14/2025 12:25:00 PM
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action - PCRX - Pacira BioSciences ( NASDAQ:PCRX ) 3/14/2025 12:04:00 AM
Pacira BioSciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 14, 2025 Deadline to file Lead Plaintiff Motion - Pacira BioSciences ( NASDAQ:PCRX ) 3/13/2025 7:25:00 PM
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX - Pacira BioSciences ( NASDAQ:PCRX ) 3/13/2025 4:58:00 PM
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Pacira BioSciences ( NASDAQ:PCRX ) 3/9/2025 12:31:00 PM
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX - Pacira BioSciences ( NASDAQ:PCRX ) 3/7/2025 2:38:00 PM
PCRX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action - PCRX - Pacira BioSciences ( NASDAQ:PCRX ) 3/6/2025 8:24:00 PM

Financial Details for PCRX

Company Overview

Ticker PCRX
Company Name Pacira BioSciences Inc
Country USA
Description Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/5/2025

Stock Price History

Last Day Price 24.91
Price 4 Years Ago 60.17
Last Day Price Updated 3/28/2025 8:42:30 PM EST
Last Day Volume 586,569
Average Daily Volume 906,757
52-Week High 31.67
52-Week Low 11.16
Last Price to 52 Week Low 123.21%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE 15.93
Free Cash Flow Ratio 2.54
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 2.25
Total Cash Per Share 9.81
Book Value Per Share Most Recent Quarter 16.83
Price to Book Ratio 1.50
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 1.67
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 46,276,200
Market Capitalization 1,152,740,142
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -38.10%
Annual Earnings Growth 163.72%
Reported EPS 12 Trailing Months -2.23
Reported EPS Past Year 3.21
Reported EPS Prior Year 2.92
Net Income Twelve Trailing Months -98,759,000
Net Income Past Year 41,955,000
Net Income Prior Year 15,909,000
Quarterly Revenue Growth YOY 3.30%
5-Year Revenue Growth 13.54%
Operating Margin Twelve Trailing Months 15.80%

Balance Sheet

Total Cash Most Recent Quarter 453,810,000
Total Cash Past Year 278,581,000
Total Cash Prior Year 288,651,000
Net Cash Position Most Recent Quarter -133,547,000
Net Cash Position Past Year -243,856,000
Long Term Debt Past Year 522,437,000
Long Term Debt Prior Year 689,471,000
Total Debt Most Recent Quarter 587,357,000
Equity to Debt Ratio Past Year 0.62
Equity to Debt Ratio Most Recent Quarter 0.56
Total Stockholder Equity Past Year 870,130,000
Total Stockholder Equity Prior Year 775,010,000
Total Stockholder Equity Most Recent Quarter 749,583,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -8,463,000
Free Cash Flow Per Share Twelve Trailing Months -0.18
Free Cash Flow Past Year 139,488,000
Free Cash Flow Prior Year 115,198,000

Options

Put/Call Ratio 0.08
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.09
MACD Signal -0.13
20-Day Bollinger Lower Band 15.54
20-Day Bollinger Middle Band 21.86
20-Day Bollinger Upper Band 28.18
Beta 0.86
RSI 58.26
50-Day SMA 21.36
150-Day SMA 34.77
200-Day SMA 41.41

System

Modified 3/28/2025 4:31:32 AM EST